InsidersTradesSigma
Follow the Dianthus Therapeutics, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €6.2bn. The latest transaction was reported on 10 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: ADAM VENESS. Every trade is openly available.
Analysts rate Dianthus Therapeutics, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$137.62.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
4 of 4 declarations
Dianthus Therapeutics, Inc. 是一家生物制药公司，专注于开发治疗自身免疫性疾病的创新疗法。该公司专门从事改善患者生活质量的药物的研发和商业化。